# Cerebral Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cerebral-therapeutics

- Industry: Biotechnology
- Headquarters: Aurora, US
- Website: www.cerebraltherapeutics.com
- Total disclosed funding: $86M
- Latest round: Series C (Jun 28, 2022)
- Investors on record: 5

## About

Cerebral Therapeutics, Inc. specializes in developing innovative treatments for neurological disorders, focusing on intracerebroventricular (ICV) delivery systems that enhance therapeutic efficacy and patient outcomes.Founded in 2010 and headquartered in Aurora, US, Cerebral Therapeutics, Inc. is dedicated to addressing neurological disorders through advanced therapies. The company received Series C funding of USD 40 mn on June 28, 2022, led by Lynx1 Capital Management, along with other investors such as Granite Point Capital Management and RA Capital. Dan Abrams serves as the CEO and was involved in founding the company, which has made significant strides in its treatment pipeline since inception.Cerebral Therapeutics develops innovative therapeutic solutions designed to enhance the delivery of drugs for neurological conditions. Their focus on intracerebroventricular (ICV) delivery aims to improve the efficacy of treatments for patients suffering from various neurological disorders, ensuring that medication reaches the central nervous system effectively.The company has raised a total of USD 40 mn, with its latest funding round contributing to its financial growth. Revenue generation is primarily projected through advancements in its product offerings, such as ICV delivery methods that facilitate improved patient outcomes in neurological care.Cerebral Therapeutics plans to utilize the recent Series C funding to advance its ICV treatment pipeline, which includes in-house development initiatives and partnerships with leading biopharmaceutical companies. The company aims to expand its market presence by enhancing product offerings and exploring new geographical regions to improve patient access to their innovative therapies.

## Funding rounds

- Series C, Jun 28, 2022, $40M — Vivo Capital, Granite Point Capital Management, RA Capital Management, Perceptive Advisors, Lynx1 Capital Management
- Series B, Jan 7, 2020, $35M — Vivo Capital, Granite Point Capital Management, RA Capital Management, Perceptive Advisors
- Series A, Mar 8, 2019, $7.8M — Vivo Capital, Granite Point Capital Management
- Series A, Jun 20, 2018, $3M — Vivo Capital, Granite Point Capital Management

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B, Series C
- Granite Point Capital Management — Series A, Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Lynx1 Capital Management — Series C